Scroll to top

Scroll to top

Investors

About

Stock Quote

NASDAQIMUX

Fast Facts

Company Founded in 2016
Experts in Selective Oral Drugs in Immunology
Differentiated Development Programs
Headquartered in New York City
NASDAQ: IMUX

Latest News

June 10, 2026

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following...

May 28, 2026

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis – – Additional CALLIPER Data...

May 27, 2026

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus® – – Will Leverage Senior Global Executive and Commercial Experience to Support Immunic's...

View All

Immunic Therapeutics
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

LifeSci Advisors
Joyce Allaire
Managing Director
immunic@lifesciadvisors.com